NFKB1 and diabetes mellitus: Collectively, the results suggest that AME can inhibit the AGE-induced production of inflammatory cytokines in macrophages to down-regulate inflammation through p38 MAPK and NF-κB signaling pathways, indicating its potential application as an immunoregulatory agent in diabetes.